A group representing mayors of cities across the country is pushing the federal government to enact a series of major marijuana law reforms.
The U.S. Conference of Mayors is also calling on cities in states that have legalized cannabis to expunge people’s past convictions.
“The looming threat of federal prosecution or shutdown lends uncertainty to states and local governments and legally compliant commercial cannabis business operators, patients and adult-use consumers, and harms state and local efforts to regulate cannabis for the safety and health of its residents,” reads one of the two measures adopted by the mayors group on Monday.
“The United States Conference of Mayors urges the White House, U.S. Department of Justice and the U.S. Drug Enforcement Administration to immediately remove cannabis from the schedule of the CSA to enable U.S. federal banking regulators to permanently authorize financial institutions to provide services to commercial cannabis businesses, and increase the safety of the public.”
The mayors are also asking federal officials to maintain Obama-era guidance that provides some protections to banks that work with cannabis businesses.
And the measure—sponsored by the mayors of Denver, Las Vegas, Los Angeles, San Francisco, Seattle and other cities—presses Congress to pass a series of amendments to federal spending bills that would continue to shield state medical marijuana programs and add new protections for broader recreational laws as well as additional reforms “to address financial services access challenges for commercial cannabis businesses and extend safe and legal access to veterans.”
The other resolution, on expungements, details the racially “discriminatory enforcement” of prohibition and “calls on local governments, where marijuana has been legalized, to act, moving with urgency to vacate misdemeanor marijuana convictions for conduct that is now deemed legal.”
“The decades long and failed war on drugs has devastated communities of color across our nation and incarcerated a disproportionate and unprecedented amount of people from those communities.”
“A drug conviction, even for the misdemeanor offense of possession of marijuana, can have significant negative consequences affecting a person’s employment opportunities, education options, qualification for government benefits and programs, travel, and immigration status,” the measure says. “Vacating these convictions serves as evidence that the criminal justice system acknowledges the racial disproportionality of enforcement of drug laws and is willing to address that injustice.”
“When government policies create injustice, the government has an obligation to correct that injustice.”
The measures were approved by the Conference’s Criminal and Social Justice Committee on Saturday and then adopted on Monday by the full body, which represents mayors leading the 1,408 U.S. cities with populations of 30,000 or more.
In a related development, several major city mayors are joining together to form a new organization to pressure the federal government to modernize its cannabis laws and to “share best practices among local governments to help advance responsible local control over marijuana.”
Mayors are the ones implementing legal marijuana. We know what works & what doesn’t. Teaming up w/ @MarkFarrellSF, @MayorJenny, @LibbySchaaf, @tedwheeler & @mayorheidi in a first-of-its-kind coalition to help cities, states & Congress prepare for legalization #MayorsMJCoalition pic.twitter.com/M6TCORQc5P
— Michael B. Hancock (@MayorHancock) June 11, 2018
The Government for Responsible U.S. Cannabis Policy Coalition will work to “establish a national framework to proactively prepare governments for implementation of legalized marijuana.”
Seattle Mayor Jenny Durkan, who sponsored the expungement resolution, said she was motivated by the unfairness in marijuana enforcement rates.
“Vacating charges for misdemeanor marijuana possession is a necessary step to correct the injustices of what was a failed War on Drugs, which disproportionately affected communities of color in our nation,” she said in a press release. “The unanimous passage of this resolution proves that city leaders recognize the harm that the failed policies had on people who needed opportunity and treatment. I encourage local leaders to act with urgency in their own cities to give their residents – including immigrants and refugees – a clean slate.”
At the #USCM2018, I’m offering a resolution encouraging local governments to vacate charges for misdemeanor marijuana possession – a necessary step to correct the injustices of the failed war on drugs. Thank you to Criminal & Social Justice Committee & @karenaboutgary for passing
— Mayor Jenny Durkan (@MayorJenny) June 9, 2018
The mayors’ action comes just days after the governors of 12 states joined together to push Congress to pass far-reaching marijuana legislation.
A bipartisan group of 14 members of Congress sent a letter to the mayors endorsing their resolution calling for federal reforms.
“Today, more than half of the American population live in states that have adopted cannabis laws. Many of these responsible and reasonable state-approved policies were supported by voters,” they wrote. “According to recent polls, most Americans support the legalization of cannabis. It is evident that a different federal approach to the issue of cannabis is appropriate, necessary, and supported by a majority of the American public.”
“Your resolution recognizes the realities of cannabis and advocates for many of the same policies that we support.”
The mayors group has passed several marijuana-related resolutions at past conferences.
In 2013, for example, it adopted a measure saying that “states and localities should be able to set whatever marijuana policies work best to improve the public safety and health of their communities…without federal interference.”
Marijuana Moment supporters on Patreon can read the full text of the two new cannabis resolutions adopted by mayors, as well as the letter that members of Congress sent endorsing one of the measures, below:
Feds Send Warning Letter To Another CBD Company Over Medical Claims
The Food and Drug Administration (FDA) and Federal Trade Commission (FTC) sent a warning letter to a Florida-based CBD company on Tuesday, alleging that the business made several unsanctioned claims about the therapeutic benefits of their products.
The federal agencies accused Rooted Apothecary of unlawfully asserting that their cannabidiol products could treat symptoms of conditions such as ADHD, Parkinson’s disease, ear aches, ADHD and autism. Those claims appeared on the company’s website and social media accounts, they said.
Certain products appeared to be marketed as dietary supplements, which FDA currently prohibits as it works to develop an alternative regulatory scheme for CBD.
“Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance,” Acting FDA Commissioner Ned Sharpless said in a press release. “We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat, or cure a number of diseases or conditions.”
FDA and FTC have issued a joint warning letter to a company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease, among other conditions/diseases. https://t.co/tsn4SBiGzH pic.twitter.com/sG3wyURMDS
— Dr. Ned Sharpless (@FDACommissioner) October 22, 2019
We’ve sent numerous warning letters that focus on matters of significant public health concern to CBD companies, and these actions should send a message to the broader market about complying with FDA requirements.
— Dr. Ned Sharpless (@FDACommissioner) October 22, 2019
“We’ve sent numerous warning letters that focus on matters of significant public health concern to CBD companies, and these actions should send a message to the broader market about complying with FDA requirements,” he said. “As we examine potential regulatory pathways for the lawful marketing of cannabis products, protecting and promoting public health through sound, science-based decision-making remains our top priority.”
FTC’s complaint with the company is that it violated a law that requires businesses that advertise medical claims about their products to have “competent and reliable scientific evidence” to back them up, which could include human clinical trials. Making or exaggerating such claims through “a product name, website name, metatags, or other means” without proper evidence is also prohibited.
FTC and @US_FDA warn Florida company marketing CBD products about claims related to treating autism, ADHD, Parkinson’s, Alzheimer’s, and other medical conditions: https://t.co/cAbxPPcxk8 pic.twitter.com/GdlttyBgxv
— FTC (@FTC) October 22, 2019
Rooted Apothecary must respond to the agencies within 15 working days to explain what steps it’s taking to resolve the issues. If the company fails to do so, it is subject to legal action, including the possible seizure of its products or an injunction. It may also have to compensate customers.
FDA emphasized that CBD products—other than the prescription medication Epidiolex, for the treatment of intractable epilepsy—are not currently allowed. But it also reiterated that the agency is in the process of developing rules that could allow for the lawful marketing of the compound.
In April, FDA sent warning letters to three other CBD companies that it said was making unauthorized claims about the medical benefits of their products. FTC also submitted warning letters to three separate CBD companies for allegedly advertising misleading statements about their products last month.
These letters are examples of the agency’s use of enforcement discretion. Former FDA Commissioner Scott Gottlieb, who recently suggested that the federal government should be involved in regulating state marijuana programs, clarified in March that the agency is only going after companies that make especially misleading claims about their products.
Senate Majority Leader Mitch McConnell (R-KY), who championed a provision of the 2018 Farm Bill federally legalizing hemp and its derivatives, has urged FDA to clear a path for the lawful marketing of CBD products by using enforcement discretion while it develops an interim final rule. A bipartisan group of lawmakers made a similar request in a letter sent to the agency last month.
“The FDA is working quickly to further clarify our regulatory approach for products containing cannabis and cannabis-derived compounds like CBD while using all available resources to monitor the marketplace and protect public health by taking action as needed against companies,” FDA Principal Deputy Commissioner Amy Abernethy said.
FDA’s working quickly to further clarify our regulatory approach for products with cannabis/cannabis-derivatives like CBD while using all available resources to monitor the marketplace & protect public health by taking action as needed against companies. https://t.co/HB9IhG2qud
— Dr. Amy Abernethy (@DrAbernethyFDA) October 22, 2019
We are committed to advancing our regulation of these products through an approach that, in line with our mission, prioritizes public health, fosters innovation and promotes consumer confidence. We plan to provide an update on our progress in this area in the near future.
— Dr. Amy Abernethy (@DrAbernethyFDA) October 22, 2019
“We recognize that there is significant public interest in cannabis and cannabis-derived compounds; however, we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products,” she said. “We are committed to advancing our regulation of these products through an approach that, in line with our mission, prioritizes public health, fosters innovation and promotes consumer confidence.”
Photo courtesy of Kimzy Nanney.
GOP Senator Links Medical Marijuana Claims To Tobacco Industry Advertisements
Sen. John Cornyn (R-TX) said on Tuesday that claims about the therapeutic potential of marijuana remind him of decades-old tobacco industry advertisements asserting that the product had medical benefits.
In a speech on the Senate floor, Cornyn discussed a hearing that the International Narcotics Control Caucus, which he co-chairs, will hold on Wednesday to explore the public health impacts of cannabis. He said it was especially important to hear from experts about the subject as more states legalize marijuana and members of Congress, as well as Democratic presidential candidates, push to end federal prohibition.
Senate Hearing To Focus On Marijuana And Health This Week – https://t.co/aPZczm3X75
— Senator John Cornyn (@JohnCornyn) October 21, 2019
The senator made clear he’s skeptical about marijuana’s health benefits.
“There’s no shortage of people who claim that marijuana has endless health benefits and can help patients struggling from everything from epilepsy to anxiety to cancer treatments,” he said. “This reminds me of some of the advertising we saw from the tobacco industry years ago where they actually claimed public health benefits from smoking tobacco, which we know as a matter of fact were false and that tobacco contains nicotine, an addictive drug, and is implicated with cancers of different kinds.”
“We’re hearing a lot of the same happy talk with regard to marijuana and none of the facts that we need to understand about the public health impact of marijuana use,” he said.
While Cornyn recognized there’s significant support for cannabis reform, he said that ” for the number of voices in support of legalization, there are even more unanswered questions about both the short- and long-term public health effects.”
He expressed concern about increased levels of THC concentration in cannabis products and stated that it’s “true that for some people that marijuana can indeed be addictive.”
“There’s simply a lack of scientific evidence to determine the link between marijuana and various health risks, and that’s something I would think Congress and the American people would want to know before we proceed further down this path,” Cornyn said. “We don’t know enough about how this could impair cognitive function or capacity or increase the risk of mental illness or perhaps serve as a gateway for other drugs that are even more damaging to the health of a young person.”
The senator made similar remarks during a conversation with a former White House drug czar in August. He said it was important to address the public health impacts of cannabis before moving forward with legislation that would protect banks that service marijuana businesses from being penalized by federal regulators.
“With increasing use and a growing number of states giving the green light for marijuana use, we need better answers,” he said.
The surgeon general and the director of the National Institute on Drug Abuse, along with several academics, are scheduled to testify at Wednesday’s hearing.
Photo courtesy of C-SPAN.
Michael J. Fox Parkinson’s Foundation Urges Congress To Pass Three Marijuana Research Bills
A leading advocacy group that’s dedicated to finding treatment options for Parkinson’s disease is backing three pieces of marijuana research legislation in Congress.
The Michael J. Fox Foundation (MJFF)—named after the actor, who has Parkinson’s and established the nonprofit—said last week that lifting barriers to cannabis research, including rescheduling the plant under the Controlled Substances Act (CSA), is necessary to promote studies verifying marijuana’s potential therapeutic benefit for conditions such as Parkinson’s patients.
“The MJFF supports increased access to cannabis for medical research. Congress has begun to recognize this need, and there are several bills in the U.S. House and Senate designed to remove barriers that impede safe and legal access to cannabis by medical researchers,” the foundation said on its website. “The MJFF public policy team is tracking these bills and working to educate members of Congress and their staff on their importance to the Parkinson’s community.”
MJFF said it’s in favor of three marijuana bills, which would accomplish the following:
—Require the Justice Department to approve additional manufacturers for research-grade cannabis.
—Protect research institutions that conduct studies on marijuana.
—Authorize the U.S. Department of Veterans Affairs (VA) to inform patients about opportunities to participate in federally authorized cannabis studies.
—Require VA to conduct studies into the therapeutic potential of marijuana in the treatment of various conditions that commonly afflict veterans such as chronic pain and post-traumatic stress disorder.
—Reschedule marijuana from Schedule I to Schedule III under the CSA.
—Free up universities to conduct studies on cannabis by removing certain regulatory requirements.
In a letter to the Senate sponsor of that last piece of legislation, Sen. Dick Durbin (D-IL), in June, the foundation stated that marijuana’s current classification under federal law and the inadequate quality of cannabis grown at the only federally authorized manufacturing facility has meant that “researchers do not have the proper materials to conduct the necessary research.”
The foundation noted that it has submitted comments to the Food and Drug Administration arguing in favor of rescheduling in 2018 and 2019. It also applauded the Drug Enforcement Administration for announcing that it would take steps to approve additional federal cannabis farms for research.
“Current policies hinder comprehensive medical research on cannabis, making it difficult to generate the evidence needed for clear recommendations,” Andrew Koemeter-Cox, MJFF’s associate director of research programs, said. “This is especially problematic when some products may be unsafe for human use and have the potential for adverse interactions with other medications.”
Ted Thompson, the nonprofit’s senior vice president of public policy, said that removing barriers to research “is one way in which Congress can help scientific researchers determine what the benefits of medical cannabis might be for Parkinson’s disease.”
“Our role on the public policy team is to work with Congress and the administration to ensure there is access and funding for research and care initiatives that can benefit people living with Parkinson’s and, right now, that includes access to medical cannabis for research,” he said.
Photo courtesy of Brian Shamblen.